Immunovia Financial Statement 2016
2016 in Summary • Prospective validation study of the hereditary risk group for pancreatic cancer started as planned at the end of 2016. • IMMray™ PanCan–d validated in an American patient cohort. 96% accuracy confirmed for early detection of pancreatic cancer. • Collaboration with the US National Center Institute to focus on early onset diabetes patients aged over 50. • Immunovia Scientific Advisory Board in pancreatic cancer was formed. • Immunovia Board strengthened with internationally experienced commercial leaders. • World Pancreatic Cancer Coalition was formed and